Journal of Current Glaucoma Practice

Register      Login

VOLUME 6 , ISSUE 2 ( May-August, 2012 ) > List of Articles

REVIEW ARTICLE

Bevacizumab in Glaucoma: Where do We Stand?

Anjani Khanna

Keywords : Bevacizumab, Glaucoma, Intraocular pressure, VEGF

Citation Information : Khanna A. Bevacizumab in Glaucoma: Where do We Stand?. J Curr Glaucoma Pract 2012; 6 (2):75-78.

DOI: 10.5005/jp-journals-10008-1110

License: CC BY-NC 4.0

Published Online: 01-08-2012

Copyright Statement:  Copyright © 2012; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

The use of antivascular endothelial growth factors such as bevacizumab and ranibizumab has brought about a revolution in management protocols of various ophthalmic disorders. A lot has been written about these agents, still lacunae exist in our understanding due to paucity of randomized control trials with large number of patients. This brief review attempts to throw light on the clinical applications of these molecules for glaucoma.


PDF Share
  1. Michaelson, IC. Retinal circulation in man and animals. Springfield, IL: Thomas; 1954. pp. 146.
  2. Senger DR, Ledbetter SR, Claffey KP, Papadopoulos-Sergiou A, Peruzzi CA, Detmar M. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphaVbeta3 integrin, osteopontin, and thrombin. Am J Pathol 1996 Jul;149(1):293-305.
  3. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperper-meability and angiogenesis. Am J Pathol 1995 May;146(5):1029-1039.
  4. Aiello LP, Wong JS. Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int Suppl 2000 Sep;77:S113-S119.
  5. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, et al. Vascular Endothelial Growth Factor in ocular fluid of patients with DR and other retinal disorders. N Engl J Med 1994 Dec;331(22):1480- 1487.
  6. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al. Bevacizumab plus irnotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-2342.
  7. Shazly TA, Latina MA. Neovascular glaucoma: Etiology, diagnosis and prognosis. Semin Ophthalmol 2009 Mar- Apr;24(2):113-121.
  8. Kuang TM, Liu CJ, Chou CK, Hsu WM. Clinical experience in the management of neovascular glaucoma. J Chin Med Assoc 2004 Mar;67(3):131-135.
  9. Sivak-Callcott JA, O'Day DM, Gass JD, Tsai JC. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology 2001 Oct;108(10):1767-1776.
  10. Tripathi RC, Li J, Tripathi BJ, Chalam KV, Adamis AP. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology 1998 Feb;105(2):232-237.
  11. Grover S, Gupta S, Sharma R, Brar VS, Chalam KV. Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma. Br J Ophthalmol 2009 Feb;93(2):273-274.
  12. Kahook MY, Schuman JS, Noecker RJ. Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Lasers Imaging 2006 Mar-Apr;37(2):144-146.
  13. Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006 Mar;26(3):352-354.
  14. Davidorf FH, Mouser JG, Derick RJ. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina 2006 Mar;26(3):354-356.
  15. Iliev ME, Domig D, Wolf-Schnurrbursch U, Wolf S, Sarra GM. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 2006 Dec;142(6):1054- 1056.
  16. Oshima Y, Sakaguchi H, Gomi F, Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2006 Jul;142(1):155-158.
  17. Grisanti S, Biester S, Peters S, Tatar O, Ziemssen F, Bartz-Schmidt KU, Tuebingen Bevacizumab Study Group. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol 2006 Jul;142(1):158-160.
  18. Sasamoto Y, Oshima Y, Miki A, Wakabayashi T, Song D, Matsushita K, Hamasaki T, Nishida K. Clinical outcomes and changes in aqueous vascular endothelial growth factor levels after intravitreal bevacizumab for iris neovascularization and neovascular glaucoma: A retrospective two-dose comparative study. J Ocul Pharmacol Ther 2012 Feb;28(1):41-48.
  19. Gheith ME, Siam GA, de Barros DS, Garg SJ, Moster MR. Role of intravitreal bevacizumab in neovascular glaucoma. J Ocul Pharmacol Ther 2007 Oct;23(5):487-491.
  20. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007 May;114(5):855-859.
  21. Wakabayashi T, Oshima Y, Sakaguchi H, Ikuno Y, Miki A, Gomi F, Otori Y, Kamei M, Kusaka S, Tano Y. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 2008 Sep;115(9):1571-1580;1580.
  22. Altintas AG, Arifoglu HB, Tutar E, Koklu G, Ozcan PY. Effect on anterior chamber bevacizumab injection combined with seton implantation in treatment of rubeosis iridis in Neovascular Glaucoma. Cutan Ocul Toxicol 2012 Jun;31(2):124-127.
  23. Marey HM, Ellakwa AF. Intravitreal bevacizumab with or without mitomycin C trabeculectomy in the treatment of neovascular glaucoma. Clin Ophthalmol 2011;5:841-845.
  24. Cornish KS, Ramamurthi S, Saidkasimova S, Ramaesh K. Intravitreal bevacizumab and augmented trabeculectomy for neovascular glaucoma in young diabetic patients. Eye (Lond) 2009 Apr;23(4):979-981.
  25. Yoshida N, Hisatomi T, Ikeda Y, Kohno R, Murakami Y, Imaki H, Ueno A, Fujisawa K, Ishibashi T. Intravitreal bevacizumab treatment for neovascular glaucoma: Histopathological analysis of trabeculectomy specimens. Graefes Arch Clin Exp Ophthalmol 2011 Oct;249(10):1547-1552.
  26. Horsley MB, Kahook MY. Anti-VEGF therapy for glaucoma. Curr Opin Ophthalmol 2010 Mar,21(2):112-117.
  27. Van Bergen T, Vandewalle E, Van de Veire S, Dewerchin M, Stassen JM, Moons L, Stalmans I. The role of different VEGF isoforms in scar formation after glaucoma filtration surgery. Exp Eye Res 2011 Nov;93(5):689-699.
  28. Kahook MY, Schuman JS, Noecker RJ. Needle bleb revision of encapsulated filtering bleb with bevacizumab. Ophthalmic Surg Lasers Imaging 2006 Mar-Apr;37(2):148-150.
  29. Kapetansky FM, Pappa KS, Krasnow MA, Baker ND, Francis CD. Subconjunctival injection[s] of bevacizumab for failing filtering blebs. Invest Ophthalmol Vis Sci 2007 May;48:837.
  30. Grewal DS, Jain R, Kumar H, Grewal SP. Evaluation of subconjunctival bevacizumab as an adjunct to trabeculectomy a pilot study. Ophthalmology 2008 Dec;115(12):2141-2145.
  31. Nilforushan N, Yadgari M, Kish SK, Nassiri N. Subconjunctival bevacizumab versus mitomycin C adjunctive to trabeculectomy. Am J Ophthalmol 2012 Feb;153(2):352-357.
  32. Sedghipour MR, Mostafaei A, Taghavi Y. Low-dose subconjunctival bevacizumab to augment trabeculectomy for glaucoma. Clin Ophthalmol 2011;5:797-800.
  33. Higashide T, Murotani E, Saito Y, Ohkubo S, Sugiyama K. Adverse events associated with intraocular injections of bevacizumab in eyes with neovascular glaucoma. Graefes Arch Clin Exp Ophthalmol 2012 Apr;250(4):603-610.
  34. Wittström E, Holmberg H, Hvarfner C, Andréasson S. Clinical and electrophysiologic outcome in patients with neovascular glaucoma treated with and without bevacizumab. Eur J Ophthalmol 2012 Jul-Aug;22(4):563-574.
  35. Chua BE, Nguyen DQ, Qin Q, Ruddle JB, Wells AP, Niyadurupola N, Gupta V, Wong TT, Coote MA, Crowston JG. Bleb vascularity following post-trabeculectomy subconjunctival bevacizumab: A pilot study. Clin Experiment Ophthalmol 2012 Nov;40(8):773-779.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.